Artemisinin Anticancer Mechanisms

Exhibit potent, multi-targeted anticancer activity across diverse solid tumors and hematological malignancies.

Artemisinin and its semi-synthetic derivatives—such as artesunate (ART), dihydroartemisinin (DHA), and artemether—exhibit potent, multi-targeted anticancer activity across diverse solid tumors and hematological malignancies. Their antitumor action operates through several interrelated biological mechanisms:

1. Iron-Mediated Bioactivation & Generation of ROS

• Endoperoxide Bridge Cleavage: The central chemical driver of artemisinin’s cytotoxicity is its rare 1,2,4-trioxane endoperoxide bridge. In the presence of free intracellular ferrous iron (Fe2+) or iron-containing heme, this peroxide bond breaks down via Fenton-type reactions, generating primary and secondary carbon-centered alkylating radicals and reactive oxygen species (ROS).

• Selective Toxicity via Iron Metabolism: Rapidly proliferating cancer cells overexpress transferrin receptor 1 (TfR-1 / CD71) to absorb large quantities of iron. As a result, cancer cells accumulate higher intracellular iron pools than normal cells, making them uniquely susceptible to artemisinin activation. Preloading cells with holo-transferrin or iron enhances toxicity up to 100-fold, whereas iron chelators like desferrioxamine (DFO) block cell death.

• Oxidative Damage: Because tumor cells frequently express lower baseline levels of antioxidant enzymes (e.g., superoxide dismutase, catalase, glutathione peroxidase), elevated ROS levels cause catastrophic oxidative damage to cellular lipid membranes, proteins, and nuclear DNA.

2. Induction of Apoptosis & Alternative Cell Death Pathways

• Intrinsic (Mitochondrial) Apoptosis: ARTs shift the Bcl-2 family balance by upregulating pro-apoptotic Bax and Bak while downregulating anti-apoptotic Bcl-2 and Bcl-xL. This induces loss of mitochondrial membrane potential (Δψm), cytochrome c release, and downstream activation of caspase-9 and caspase-3.

• Extrinsic & ER Stress Pathways: DHA upregulates death receptor 5 (DR5), enhancing TRAIL-mediated apoptotic signaling and activating caspase-8. ARTs also induce iron-dependent endoplasmic reticulum (ER) stress, accelerate degradation of the c-MYC oncoprotein, and deplete survivin.

• Ferroptosis & Oncosis: In certain iron-rich tumor cells (such as head and neck squamous cell carcinoma), DHA triggers ferroptosis—an iron-dependent form of cell death driven by lipid peroxidation and depletion of glutathione peroxidase 4 (GPX4). In other phenotypes, ARTs trigger autophagy or oncosis-like cell death.

3. Cell Cycle Arrest

ARTs halt uncontrolled cell division by modulating key cell cycle regulatory proteins and checkpoints:

• G0/G1 Phase Arrest: Most commonly, ARTs induce G0/G1 arrest by downregulating cyclin-dependent kinases (CDK2, CDK4, CDK6) and cyclins D1 and E. Artemisinin directly disrupts Sp1 and NF−κB transcriptional activity on the CDK4 promoter. Additionally, ARTs downregulate the oncogenic phosphatase CDC25A and increase cyclin-dependent kinase inhibitors (p16, p21, p27).

• G2/M Phase Arrest: In specific cancer lines (e.g., breast and ovarian cancers), artesunate triggers G2/M arrest by upregulating the autophagy initiator Beclin1, altering cyclin B1, or disrupting mitotic spindle regulators (Bub3, Mad2).

4. Inhibition of Tumor Angiogenesis

To suppress new blood vessel growth required for solid tumor expansion, ARTs interfere with multiple pro-angiogenic factors:

• Growth Factor Suppression: ARTs downregulate vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), angiopoietin-1, and hypoxia-inducible factor 1α (HIF-1α).

• Receptor Downregulation: ARTs reduce VEGF receptor expression on vascular endothelial cells, including VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1), and VEGFR-3.

• NF−κB Pathway Inhibition: By blocking NF−κB DNA-binding activity, DHA suppresses downstream inflammatory and angiogenic targets such as cyclooxygenase-2 (COX-2) and interleukin-8 (IL-8).

5. Suppression of Invasion & Metastasis

ARTs attenuate the migratory and invasive capacity of aggressive tumor cells:

• Protease Inhibition: ARTs decrease expression and activity of matrix metalloproteinases (MMP-2, MMP-7, MMP-9) by inactivating AP-1 and NF−κB transcription factors.

• Cell Adhesion Modulation: ARTs restore cell-cell adhesion by increasing E-cadherin and tissue inhibitor of metalloproteinases 2 (TIMP-2) expression while downregulating αvβ3 integrin.

6. Overcoming Multidrug Resistance & Chemosensitization

• Independence from Drug Efflux Pumps: Unlike conventional chemotherapy, artemisinin activity is unaffected by the overexpression of classical multidrug resistance transporters, such as P-glycoprotein (MDR1/Pgp), MRP1, or BCRP.

• Chemosensitization: When combined with standard agents (e.g., gemcitabine, cisplatin, temozolomide, epirubicin, or oxaliplatin), artesunate and DHA exhibit synergistic effects, enhancing apoptosis and reversing drug resistance.

  ---

  References

  1. Cheng, C., Ho, W. E., Guan, S. P., Kong, L. R., Hafiz, W., Goh, F. Y., Leung, B. P., & Wong, W. S. F. (2011). Antimalarial drug artesunate attenuates experimental allergic asthma via inhibition of the phosphoinositide 3-kinase/Akt pathway. PLOS ONE, 6(6), Article e20932. [Source: pone.0020932.pdf]

  2. Crespo-Ortiz, M. P., & Wei, M. Q. (2012). Antitumor activity of artemisinin and its derivatives: From a well-known antimalarial agent to a potential anticancer drug. Journal of Biomedicine and Biotechnology, 2012, Article 247597. https://doi.org/10.1155/2012/247597 [Source: BioMed Research International - 2011 - Crespo-Ortiz...pdf]

  3. Krishna, S., Bustamante, L., Haynes, R. K., & Staines, H. M. (2008). Artemisinins: Their growing importance in medicine. Trends in Pharmacological Sciences, 29(10), 520–527. [Source: PIIS0165614708001648.pdf]

  4. Krishna, S., Ganapathi, S., Chis Ster, I., Saeed, M. E. M., Cowan, M., Finlayson, C., Kovacsevics, H., Jansen, H., Kremsner, P. G., Efferth, T., & Kumar, D. (2015). A randomized, double blind, placebo-controlled pilot study of oral artesunate therapy for colorectal cancer. EBioMedicine, 2(1), 82–90. https://doi.org/10.1016/j.ebiom.2014.11.010 [Source: PIIS2352396414000346.pdf]

  5. Li, Y. (2012). Qinghaosu (artemisinin): Chemistry and pharmacology. Acta Pharmacologica Sinica, 33(9), 1141–1146.[Source: aps2012104a.pdf]

  6. Li, Z., Li, Q., Wu, J., Wang, M., & Yu, J. (2016). Artemisinin and its derivatives as a repurposing anticancer agent: What else do we need to do? Molecules, 21(10), Article 1331. [Source: molecules-21-01331-v2.pdf]

  7. Liu, L., et al. (2015). Antitumor effect of artesunate on human esophageal carcinoma cells in vitro and in vivo. Molecular Medicine Reports, 12(1), 1465–1471. [Source: mmr_12_1_1465_PDF.pdf]

  8. Liu, T., Liu, Q.-L., et al. (2013). Targeted cytotoxicity of artesunate towards retinoblastoma cells via CD71-mediated endocytosis. Oncology Reports, 30(3), 1473–1480. [Source: or_30_3_1473_PDF.pdf]

  9. Slezakova, S., & Ruda-Kucerova, J. (2017). Anticancer activity of artemisinin and its derivatives. Anticancer Research, 37(11), 5995–6003. https://doi.org/10.21873/anticanres.12046 [Source: 5995.full.pdf]